Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, Tedisamil (Pulzium®) cannot be endorsed for use within NHS Wales for the treatment of atrial fibrillation. |
||
|
||
Medicine details |
||
| Medicine name | tedisamil (Pulzium®) | |
| Formulation | 2 mg/ml concentrate for solution for infusion | |
| Reference number | 298 | |
| Indication | For the treatment of atrial fibrillation |
|
| Company | Solvay Healthcare Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 01/09/2009 | |